ASH-SAP, Eighth Edition
The American Society of Hematology Self-Assessment Program (ASH-SAP), Eighth Edition, is intended to serve as a resource for trainees, both as a topic review and as a means to prepare for specialty board certification. ASH-SAP is also intended for practicing hematologists, both as an update in the discipline and as an opportunity to earn continuing medical education (CME) credit and points toward American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC). Learners can claim up to 75 hours of CME credit and/or ABIM MOC credit through a series of 6 test modules covering the content of the eighth edition of ASH-SAP.
A major goal of ASH-SAP is to provide challenging and informative multiple-choice questions for hematologists preparing for professional certification or recertification exams, especially the ABIM hematology examinations. Toward that end, the multiple-choice questions in ASH-SAP are intended to be challenging and are designed to reinforce educational concepts from the chapters that are expanded on in the critiques. In this edition of ASH-SAP, all multiple-choice questions and critiques are new, and almost all questions are case based, reflecting the style of questions used in professional examinations. Each question and each critique have undergone a 3-step review by content experts, the editors, and an independent medical writer with expertise in the construction of case-based vignettes.
To claim up to 75 CME/MOC credits based on the ASH-SAP Eighth Edition, visit the ASH Academy On Demand.
About the Editors
Jessica K. Altman, MD (Senior Executive Editor)
Dr. Altman is a professor in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. She also serves as Director of the Acute Leukemia Program at Robert H. Lurie Cancer Center of Northwestern University and is a member of the Northwestern Medicine Developmental Therapeutics Program, the Signal Transduction in Cancer Program, and the Hematologic Malignancies Program at the Robert H. Lurie Cancer Center. Dr. Altman received her medical degree from the University of Pittsburgh. She completed her residency in internal medicine at the University of Chicago and a fellowship in hematology and oncology at Northwestern McGaw/Northwestern Memorial Hospital. She is board certified in hematology. Dr. Altman’s clinical and research interests include acute and chronic leukemias, anemia, myelodysplastic syndromes, and myeloproliferative diseases.
Molly Weidner Mandernach, MD, MPH, FACP (Junior Executive Editor)
Dr. Mandernach is an associate professor of medicine at University of Florida (UF) Health who practices nonmalignant hematology. She received her medical degree from the University of Florida and completed an internal medicine residency and a hematology/oncology fellowship at the University of Florida. She is the medical director of the Adult Sickle Cell Program at UF Health and is currently board certified in internal medicine, hematology, and oncology.
Rakhi P. Naik, MD, MHS (Associate Editor—Medical Education and Multimedia)
Dr. Naik is an associate professor of medicine at Johns Hopkins University. She also serves as clinical director of the Division of Hematology and associate program director for the Johns Hopkins Hematology Fellowship Track. She received her MD from Cornell Medical School and completed her residency, chief residency, and hematology fellowship at Johns Hopkins. She also holds a master’s degree in health sciences from the Johns Hopkins Bloomberg School of Public Health. Her research interests include sickle cell disease and sickle cell trait.
Matthew Ulrickson, MD, MS (Associate Editor—Question Writing)
Dr. Ulrickson is on the staff of the Division of Cancer Medicine at Banner MD Anderson Cancer Center in Gilbert, Arizona, where he is the section chief for hematology and vice chair of the Department of Oncology. He is also an assistant professor at the University of Texas (adjunct) and the University of Arizona. He completed a residency at Massachusetts General Hospital and a fellowship at the Fred Hutchinson Cancer Research Center. His clinical and research interests include acute leukemia and cellular therapy.